TET vs. ZTF, SYNT, ESNT, ELM, VCT, GFM, KMR, FXPO, GGP, and SOLG
Should you be buying Treatt stock or one of its competitors? The main competitors of Treatt include Zotefoams (ZTF), Synthomer (SYNT), Essentra (ESNT), Elementis (ELM), Victrex (VCT), Griffin Mining (GFM), Kenmare Resources (KMR), Ferrexpo (FXPO), Greatland Gold (GGP), and SolGold (SOLG). These companies are all part of the "basic materials" sector.
Treatt (LON:TET) and Zotefoams (LON:ZTF) are both small-cap basic materials companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.
In the previous week, Treatt had 1 more articles in the media than Zotefoams. MarketBeat recorded 2 mentions for Treatt and 1 mentions for Zotefoams. Treatt's average media sentiment score of 0.63 beat Zotefoams' score of 0.40 indicating that Treatt is being referred to more favorably in the media.
Treatt has higher revenue and earnings than Zotefoams. Zotefoams is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.
Treatt presently has a consensus price target of GBX 655, suggesting a potential upside of 36.14%. Given Treatt's higher possible upside, equities research analysts plainly believe Treatt is more favorable than Zotefoams.
Treatt has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Zotefoams has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Zotefoams received 87 more outperform votes than Treatt when rated by MarketBeat users. Likewise, 69.49% of users gave Zotefoams an outperform vote while only 68.83% of users gave Treatt an outperform vote.
70.1% of Treatt shares are held by institutional investors. Comparatively, 75.1% of Zotefoams shares are held by institutional investors. 12.3% of Treatt shares are held by company insiders. Comparatively, 18.7% of Zotefoams shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Treatt pays an annual dividend of GBX 8 per share and has a dividend yield of 1.7%. Zotefoams pays an annual dividend of GBX 7 per share and has a dividend yield of 1.6%. Treatt pays out 4,444.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zotefoams pays out 3,684.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Treatt has a net margin of 7.42% compared to Zotefoams' net margin of 7.28%. Zotefoams' return on equity of 8.20% beat Treatt's return on equity.
Summary
Treatt beats Zotefoams on 11 of the 19 factors compared between the two stocks.
Get Treatt News Delivered to You Automatically
Sign up to receive the latest news and ratings for TET and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
